The EPS beat and NDA submission are positive catalysts. Watch for ASCO presentation (June 2026) and potential FDA acceptance of NDA. The cash runway into 2028 removes near-term financing risk. Monitor for any regulatory updates on varegacestat and initial data from IM-1021 later in 2026.
Price Chart
Executive Summary
Immunome reported Q1 2026 results: net loss of $53.8M ($-0.48/share) vs consensus $-0.60, a beat of 20% on EPS. The NDA submission for varegacestat in desmoid tumors is the key catalyst, with ASCO oral presentation and EU MAA planned. Cash runway into 2028 supports pipeline execution.
Key Financial Metrics
Key Facts
- NDA submitted to FDA for varegacestat in desmoid tumors (April 2026)
- Phase 3 RINGSIDE data selected for oral presentation at ASCO 2026
- Q1 2026 net loss $53.8M ($-0.48/share) vs consensus $-0.60 — 20% beat
- Cash and equivalents $582.7M, runway into 2028
- IND clearance received for IM-1617 (solid tumor ADC) in April 2026
- Phase 1 trial of IM-3050 (FAP-targeted radiotherapy) initiated March 2026
- Collaboration revenue declined to $0 from $2.9M YoY (prior period had revenue)
Financial Impact
EPS beat of 20% vs consensus; cash burn $53.8M/quarter; $582.7M cash position
Risk Factors
- FDA regulatory risk for varegacestat NDA — no guarantee of approval
- No collaboration revenue in Q1 2026 vs $2.9M in Q1 2025
- Operating loss widening to $59.3M from $44.6M YoY
- Pre-revenue biotech — entirely dependent on pipeline success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-219367 |
| Document: imnm-20260512.htm | 0001193125-26-219367 |
| Document: 0001193125-26-219367-index-headers.html | 0001193125-26-219367 |
| Document: 0001193125-26-219367-index.html | 0001193125-26-219367 |
| Document: 0001193125-26-219367.txt | 0001193125-26-219367 |
| 8-K Data (Synthetic) | 0001193125-26-219367 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 1d ago | ANALYST-UPGRADE | $21.58 awaiting T+5 | awaiting T+5 | — | $20.90 (−3.15%) |
Sep 21, 2026 11d ago | ANALYST-UPGRADE | $25.07 $21.68 | ▼ −13.52% | ▼ −13.24% | $20.90 (−16.63%) |
Aug 12, 2026 7w ago | Insider Cluster | $26.42 $28.08 | ▲ +6.28% | ▲ +8.25% | $20.90 (−20.89%) |
Aug 10, 2026 7w ago | Insider Cluster | $26.25 $27.56 | ▲ +4.99% | ▲ +5.39% | $20.90 (−20.38%) |
Jul 9, 2026 12w ago | Insider Cluster | $23.35 $22.20 | ▼ −4.93% | ▼ −4.36% | $20.90 (−10.49%) |
Jul 7, 2026 12w ago | Insider Cluster | $24.01 $22.59 | ▼ −5.91% | ▼ −6.78% | $20.90 (−12.95%) |
Jul 7, 2026 12w ago | Insider Cluster | $24.01 $22.59 | ▼ −5.91% | ▼ −6.78% | $20.90 (−12.95%) |
Jul 3, 2026 13w ago | Insider Cluster | $23.61 $24.17 | ▼ −2.37% | ▼ −1.44% | $20.90 (+11.48%) |
May 28, 2026 18w ago | ANALYST-UPGRADE | $22.54 $19.81 | ▼ −12.11% | ▼ −12.06% | $20.90 (−7.28%) |
May 12, 2026 20w ago | 8-K | $22.20 $19.66 | ▼ −11.44% | ▼ −10.28% | $20.90 (−5.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access